A variety of targeted anticancer agents have been successfully introduced into clinical
practice, largely reflecting their ability to inhibit specific molecular alterations that are …

Monoclonal antibodies (mAb) are a major component of cancer therapy. In this review, we
summarize the different therapeutic mAbs that have been successfully developed against …

Glioblastoma multiforme (GBM) remains the top challenge to radiotherapy with only 25%
one-year survival after diagnosis. Here, we reveal that co-enhancement of mitochondrial …

DNA materials have emerged as potential nanocarriers for targeted cancer therapy to
precisely deliver cargos with specific purposes. The short half‐life and low bioavailability of …

Conspectus Cancer vaccines have shown tremendous potential in preventing and treating
cancer by providing immunogenic antigens to initiate specific tumor immune responses. An …

Chemotherapy is ubiquitous in first-line treatment of advanced gastric cancer, yet responses
are heterogeneous, and little is known about mediators of chemotherapy response. To move …

As one of the four major means of cancer treatment including surgery, radiotherapy (RT),
chemotherapy, immunotherapy, RT can be applied to various cancers as both a radical …

The receptor tyrosine-kinase HER2 (also known as ErbB2) is a well-established therapeutic
target in patients with breast or gastric cancer selected on the basis of HER2 overexpression …

Macrophage-mediated cellular phagocytosis (MMCP) plays a critical role in conducting
antitumor immunotherapy but is usually impaired by the intrinsic phagocytosis evading …

Trastuzumab, a targeted anti-human epidermal-growth-factor receptor-2 (HER2) monoclonal
antibody, represents a mainstay in the treatment of HER2-positive (HER2+) breast cancer …